Questions to Still be Answered in Myelofibrosis

In the NIAGARA trial, significant event-free survival and overall survival gains were observed with neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab in cisplatin-eligible bladder cancer.

Patient-reported outcomes from DESTINY-Breast06 show trastuzumab deruxtecan improved time to deterioration for pain and other subscores, with no decline in overall QOL in either arm in the HER2 low/ultralow breast cancer setting.

Atezolizumab following vemurafenib and cobimetinib shows improved overall survival in BRAF V600–positive melanoma, but not statistically significant.

In an updated analysis of the phase 3 CheckMate 77T study, perioperative nivolumab showed event-free survival benefits for the treatment of resectable non–small cell lung cancer.

Long-term findings from KEYNOTE-006, a phase 3 trial, support pembrolizumab as a standard-of-care for patients with advanced melanoma.

TORL-1-23 was well tolerated and showed efficacy in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.